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The sensitivity of patient reported outcomes (PROs) to detect the effects of treatment 
change depends on the match between the change in items of the PRO and the 
change that takes place in a sample of people. The aim of this study is to compare 
the sensitivity of different PROs in detecting changes following the initiation of 
biologic treatment in asthma. 
Methods 
Patients starting a biologic treatment as part of clinical care completed the Asthma 
Control Questionnaire (ACQ-6), the Severe Asthma Questionnaire (SAQ and SAQ-
global scores) and the EQ5D (EQ-5D-5L and EQ5D-VAS) at baseline. They 
completed the ACQ-6, SAQ, SAQ-global and a retrospective global rating of change 
(GRoC) scale at weeks 4, 8 and 16, and completed the EQ-5D-5L and EQ5D-VAS at 
week 16. The SAQ-global and EQ5D-VAS differ but both are single item 100-point 
questions. Sensitivity was measured by Cohen’s D effect size at each of the three 
time points. 
Results 
110 patients were recruited. Depending on the time of assessment, effect size varied 
between 0.45 – 0.64 for the SAQ, between 0.50 – 0.77 for the SAQ-global; between 
0.45 – 0.69 for ACQ-6; between 0.91 - 1.22 for GRoC; 0.32 for EQ-5D-5L and 0.49 




The sensitivity to change of a questionnaire varies with the time of measurement. 
The three asthma-specific prospective measures (SAQ, SAQ-global and ACQ-6) 
have similar sensitivity to change. The single-item EQ5D-VAS was less sensitive 
than the asthma specific measures and less sensitive than the single-item SAQ-
global. The EQ-5D-5L was least sensitive.  
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Introduction 
Patient reported outcomes (PRO) form an increasingly important part of treatment 
evaluation because they measure the impact of treatment from the patient’s 
perspective. In this paper we compare four different types of PRO in their ability to 
detect change over time in severe asthma following initiation of biologic therapy: a 
symptom questionnaire measuring asthma control, two quality of life questionnaires, 
and a questionnaire of perceived change. A PRO is sensitive to change to the extent 
that the items of the questionnaire capture the changes that occur in a specific 
population for a specific treatment [1]. Each of the four types of questionnaire 
capture different kinds of change and therefore may not be equally sensitive to 
treatment. 
Asthma symptoms are, in part, associated with increased airflow obstruction leading 
to a lower forced expiratory volume in 1 second (FEV1).  The asthma control 
questionnaire (ACQ-6) is a validated questionnaire that measures asthma control by 
the severity of asthma symptoms and shows a strong correlation with lung function 
[2,3]. The ACQ-6 should therefore provide a sensitive measure of improvements in 
lung function produced by pharmacological treatment.   
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Quality of life (QoL) is affected by symptoms but also by other factors such as 
personality [4], economic status [5] and social support [6]. Small changes in 
symptoms could create large changes in QoL and the relevant questionnaires, as 
long as the QoL questionnaire measures aspects of life that change following 
improved asthma control. 
There are two types of quality of life questionnaire, disease specific and generic. As 
their names suggest, disease specific questionnaires measure only deficits 
experienced in a particular disease whereas generic questionnaires measure deficits 
across a range of diseases. The severe asthma questionnaire (SAQ) [7] is designed 
to measure the QoL deficits that occur in severe asthma and therefore may be more 
sensitive to change compared to a generic questionnaire such as the EQ5D [8], 
which is known to poorly represent the deficits of QoL in severe asthma [9] and 
therefore should be less sensitive to change. 
Measures of perceived change, such as global rating of change (GRoC) require 
people to evaluate how much they feel they have improved. These are seldom used 
as a primary outcome measures because of concerns about the accuracy of 
retrospective recall and other possible biases [10]. Retrospective recall of health 
events is known to be poor, including an underestimation of asthma symptoms [11] 
and people create implicit narratives of their treatment that can create an over-
estimation of the benefit of treatment [10].  
The aim of this study is to compare the sensitivity to change as measured by effect 





Design: An open label multi-centre sensitivity to change study, using the SAQ, other 
questionnaire measures and clinic data.  
Participants: Participants were recruited from six UK specialist severe asthma 
centres (Royal Devon & Exeter, University Hospitals Plymouth NHS Trust, North 
Bristol NHS Trust, University Hospitals Birmingham, Royal Brompton and Harefield 
Hospitals, Manchester University NHS Foundation Trust) as part of usual care. All 
patients had undertaken a full multidisciplinary assessment according to UK severe 
asthma guidelines [12]. Inclusion criteria: patients with severe asthma (GINA step 4 
& 5) commencing a biologic treatment in normal clinical care following NICE 
guidelines. 
Participants were asked to complete questionnaires at baseline and at routine 
biologic administration clinic visits (0, 4, 8, 12 and 16 weeks).  
Questionnaires 
Severe Asthma Questionnaire (SAQ): The SAQ is a validated specific scale for 
severe asthma (10) comprising 16 items measuring difficulties caused by asthma in 
16 domains over a 2 week period [7]. Responses are given on a 7-point scale that 
are averaged to form the total SAQ score and three subscales, SAQ-MyLife, SAQ-
MyMind, SAQ-MyBody [13]. In addition, the SAQ provides a SAQ-global score based 
on a single 100 point Borg-type scale. Higher scores indicate better quality of life.  
The minimum clinically important difference (MCID) is 0.5 for the SAQ and 11 for the 
SAQ-global 
Asthma Control Questionnaire (ACQ-6): The ACQ-6 has six items, of which four 
measure symptoms, one measures short acting bronchodilator use and one activity 
limitations over a 7 day period. Responses are given on a 7-point scale that 
6 
 
averaged to form the ACQ-6 score. Lower scores indicate better asthma control and 
a score of 0 to 0.75 is classified as well controlled asthma [2].  The MCID is 0.5. 
The Euroqol (EQ-5D-5L): The Euroqol is a generic health status questionnaire 
comprising five dimensions measured on a single day [8]. We used the index values 
of this scale rather than the average values, as index values are used in resourcing 
decisions. Index values were calculated using the 2012 value set for England [14]. 
Global rating of change (GRoC) Questionnaire: Patients were asked to rate the 
GRoC in terms of improvement by circling a statement ‘which best describes how 
you feel since starting your new treatment for your asthma’. The GRoC used in this 
study comprises 11 response options, no change, a little better, somewhat better, 
moderately better, a good deal better and a great deal better, with deterioration 
represented by the same quantifiers but using the word ‘worse’ [10].  
Procedure: 
After providing informed consent, patients completed baseline questionnaires (SAQ 
and ACQ-6) in the clinic before their first treatment. Patients completed 
questionnaires (SAQ, ACQ-6, GRoC) during subsequent routine clinic visits as part 
of usual care at 4 weeks, 8 weeks, 12 weeks and 16 weeks after starting treatment. 
Patients receiving benralizumab attended at 0, 4, 8 and 16 weeks and so did not 
attend clinic at 12 weeks due to the transition to an 8 weekly dosing schedule. The 
EQ-5D-5L and FEV1 was assessed at baseline and at 16 weeks. Clinical records 
were used to provide demographic details. Exacerbations requiring OCS, healthcare 
utilisation and prednisolone dose (if on maintenance OCS) were documented at 




This study received ethical approvals from the Research Ethics Committee/Health 
Research Authority (REC reference: 19/WA/0011, IRAS project ID: 250167) and was 
sponsored by University Hospitals Plymouth NHS Trust.  
Statistics 
We present the data for baseline, 4, 8 and 16 weeks only as the numbers attending 
week 12 were reduced as those receiving benralizumab did not attend. The COVID 
pandemic coincided with the start of data collection so data at 16 weeks was 
reduced because many of the health staff who were collecting data were reassigned 
to COVID related duties. For this reason we present two analyses, one intention to 
treat and one per protocol, and we used t-tests to compare the per protocol patients 
with the intention to treat after removing the per protocol patients from the intention 
to treat sample.  There is no imputation of missing data for the intention to treat 
sample: we report all valid data but only valid data. Although the sample size is 
reduced at later time points the use of the two methods of analysis has the 
advantage of providing additional calculations of sensitivity to change. 
Effect size was Cohen’s D calculated from the mean difference in score between 
baseline and follow up  divided by the pooled standard deviation, except in the case 
of GRoC where Cohen’s D was calculated from the mean score (i.e., the difference 
between the score and zero) divided by the standard deviation of the GRoC score. 
Cohen’s D provides a standardised measure of change between questionnaires and 
therefore permits comparison of questionnaires that have different scaling properties. 
Conventional interpretation of Cohen’s D is that an effect size of 0.2 is considered 








One hundred and ten patients were enrolled in the study of whom 62 were female 
and 48 male. Any patient who completed one or more questionnaires at any time 
point (0, 4, 8, 16 weeks) was included in the intention to treat sample. Twenty two 
patients completed all questionnaires at weeks 0, 4, 8, and 16 of whom 12 were 
female and 10 male and these patients form the per protocol sample. Of the 22 per 
protocol patients 18 came from one severe asthma centre. Demographic and clinical 





















Table 1. Patient characteristics, means (95% confidence intervals) 
 Intention to treat 
sample 
Per protocol sample 
 n Mean (CI) n mean 
Age, years 106 
50 
(47 – 53) 
22 51 
(44 - 59) 
Female, (%) 59 (56)    





(57.32 - 74.34 
Caucasian, (%) 91 (86)  20 (91)  








dose, mg/day 60 
12.43 
(9.64 – 15.21) 
11 10.70 
(5.90 – 5.43) 
Exacerbations in the last 12 
months requiring OCS 106 
5.43  
(4.54 – 6.31) 
22 6.50 
(4.23 – 8.77) 
Emergency Department visits 106 
2.08  
(1.09 – 3.06) 
22 2.27 
(0.58 – 5.13) 
Hospital admissions 106 
1.25 




dose, mg/yr 105 
4062 
(3238 – 4885) 
22 3766 
(2472 - 5060) 





Omalizumab  (%) 16 (15)  4 (18)  
Mepolizumab (%) 26 (25)  10 (45)  
Benralizumab  (%) 62 (59)  8 (36)  
Reslizumab  (%) 2 (2)  0  
 
Table 2 shows the mean and standard deviations for the SAQ, SAQ-global and 
ACQ-6 at baseline, 4, 8 and 16 weeks, for the EQ-5D-5L at baseline and 16 weeks, 
and for the GRoC at 4, 8, and 16 weeks. The data are shown separately for intention 
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to treat and per protocol and there was no significant difference between the 
intention to treat and per protocol group at any time point. 
 
Table 2. Means and standard deviations for questionnaires for the intention to treat 
(ITT) group (n) and the per protocol (PP) group (n=22).  
 
 
Baseline 4 weeks 8 weeks 16 weeks 




























































































































Table 3 shows the effect sizes at the three time points after baseline for all 
questionnaires as a function of the intention to treat and per protocol. Of the six 
comparisons made between the asthma specific questionnaires, the SAQ-global is 
slightly better than the other two for four comparisons and the SAQ slightly better 
than the other two for two comparisons. Overall, though variable the relative effect 
sizes are similar over time and between groups. However, the effect sizes of the EQ-






Table 3. Effect sizes (Cohen’s D) for change in questionnaire scores at three follow-
up time points for intention to treat (ITT) and per protocol (PP) samples. 
 4 weeks 8 weeks 16 weeks 
 ITT PP ITT PP ITT PP 
SAQ 0.44 0.61 0.38 0.70 0.60 0.89 
SAQ-
Global 
0.48 0.59 0.60 1.06 0.72 0.83 
ACQ-6 0.41 0.58 0.54 0.95 0.61 0.76 
EQ5D     0.32 0.49 
EQ5D-
VAS 
    0.49 0.73 
GRoC 0.91 1.01 0.94 1.81 1.20 1.89 
 
 
Table 4 shows the baseline and follow up scores for the subscales of the SAQ as a 
function of the intention to treat and per protocol, and shows similar performance 
across all comparisons. 
Table 4. Means and standard deviations for SAQ subscale scores for the intention to 
treat (ITT) group (n) and the per protocol (PP) group (n=22). 
 
Baseline 4 weeks 8 weeks 16 weeks  


















































































Table 5 shows the effect sizes at the three time points after baseline for the 
subscales of the SAQ as a function of the intention to treat and per protocol, and 
shows similar performance across all comparisons. 
 
 
Table 5. Effect sizes (Cohen’s D) for change in SAQ subscale scores at three follow-up time 
points. 
 
4 weeks 8 weeks 16 weeks  












0.42 0.69 0.41 0.84 0.58 0.97 
 












the last 12 months 
requiring OCS 
SAQ 0.25* -0.34** 
SAQ-global 0.27** -0.27** 
SAQ-My Life 0.30** -0.35** 
SAQ-My Mind 0.14 -0.27** 
SAQ-My Body 0.13 -0.29** 
ACQ-6 -0.31** 0.32* 
EQ-5D-5L 0.28** -0.28** 
EQ5D-VAS 0.34** -0.30 
 
Discussion 
The sensitivity of a questionnaire to change depends on the items of the 
questionnaire, on the treatment and on the population studied [1]. In this study 
sensitivity was assessed at three time points. The dropout rate for this study was 
high due to the pandemic, and as dropout can be non-random we provided two 
analysis, intention to treat and per protocol. Although there was no significant 
difference there is a trend for those in the per protocol to have higher effect sizes 
compared to those in the intention to treat sample.  For both the intention to treat and 
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per protocol groups, the MCID for the SAQ, SAQ-global and ACQ-6 was achieved as 
early as week 4. 
 
As we performed a per protocol analysis in addition to an intention to treat analysis, it 
is possible to compare the relative effect sizes of the questionnaires in different 
samples. Our results reveal that the relative effect size between questionnaires 
varies as a function of the population and as a function of time. Sensitivity to change 
is not an absolute property of a scale but something that varies over time and with 
the population. Previous comparisons of the sensitivity of quality of life 
questionnaires have provided comparisons at only one time point and with only one 
group [16,17]. The variability of effect size as a function of group and time should be 
recognised when comparing between questionnaires. 
Our results provide six comparisons of effect size. Some questionnaires are 
consistently better or worse than others. Some questionnaires are sometimes better 
or worse depending on which comparison is made.  
The results show that that the relative sensitivity, as measured by effect size, of the 
different questionnaires changes to some extent between the six different 
comparisons, showing that comparisons of sensitivity drawn from only one group 
and at one time may not be generalisable. There is no evidence of important 
differences in sensitivity between the SAQ, SAQ-global and ACQ-6. The SAQ-global 
is slightly more sensitive on four of the six comparisons but, given the variability in 
relative effect sizes observed between these questionnaires, there is no clear 
evidence of difference between them. 
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The effect size of the EQ-5D-5L is consistently less than all the other questionnaires 
in all comparisons. The effect size of the EQ-5D-5L is about half that of the SAQ, 
SAQ-global and ACQ-6 and it is therefore safe to conclude that the EQ-5D-5L is the 
least sensitive of the questionnaires studied. The comparative insensitivity of the EQ-
5D-5L is to be expected from a scale that only partially captures the QoL deficits of 
severe asthma on a single day [8] and findings are also consistent with evidence that 
this scale is comparatively insensitive to rehabilitation [18]. 
The sensitivity of the EQ5D-VAS was slightly better than the EQ-5D-5L, but not as 
sensitive as other scales and, in particular, less sensitive than the SAQ-global. 
Although the EQ5D-VAS and SAQ-global are single item scales varying between 0 
and 100, they differ in two respects. The EQ5D-VAS asks patients to rate health, the 
SAQ-global asks patients to rate quality of life specifically in relation to asthma. The 
EQ-5D-VAS is a scale with only the end points specified. The SAQ-global is a Borg 
scale with additional quantifiers placed at empirically derived points along the scale. 
Borg scales have been shown to be more reliable than visual analogue scales [19]. 
Our data shows that they may also be more sensitive. 
The SAQ has three subscales made up from groupings of the 16 items that make up 
the SAQ. There was no consistent difference in sensitivity for these three subscales. 
The My Body subscale was the most sensitive of the three at all three times points 
for the per protocol group but not for the intention to treat subscale, where it was 
most sensitive only at week 8. These findings illustrate how small differences in 
sensitivity can arise from differences in population and time point, again showing that 
sensitivity is not an absolute property of a questionnaire, but relative to the 




Although all three subscales of the SAQ are sensitive to the effects of treatment, only 
the My Life subscale correlates with baseline FEV1%. A larger data set has also 
shown that the correlation between FEV1% and the My Life subscale is larger than 
My Life and the My Body subscales [13]. As patients’ judgements of quality of life are 
determined by numerous factors (including dispositional mood, lung function, effects 
of treatment) these data suggest that the My Life and My Body subscales are more 
affected by factors other than lung function.  Examination of other correlations with 
other PROs demonstrated no relationship between sensitivity to change and FEV1%. 
The conclusion from these data is that the use of QoL as an outcome variable 
provides different information from change in lung function, and that both PROs and 
objective measures should be used in clinical trials as they provide different kinds of 
information about the effects of treatment. 
Our study measured change in an open label study rather than comparative change 
between placebo and active treatment. We found that a global rating of change scale 
(GRoC) had the highest sensitivity to change, but it does not follow that it is most 
sensitive in comparing placebo with active treatment. The reason is that 
retrospective measures are known to be affected by biases, including that of implicit 
theory [20]. When patients receive a new treatment, they form a narrative that the 
treatment is likely to be effective, and their response, for both placebo and treatment 
is therefore affected by this narrative [21,22].  
The high sensitivity of the SAQ-global but not the EQ5D-VAS shows that single item 
scales can sometimes be highly sensitive. The SAQ-global is derived from an earlier 
scale, the Global Quality of Life Scale (GQoL) [18]. Multi-item scales require the 
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patient to consider the components of quality of life. These components are then 
aggregated most commonly with no weighting, but sometimes as in the case of the 
EQ5D with weightings from people who are not ill. As a result, the components of the 
multi-item quality of life scale are not aggregated using the patient’s own individual 
utilities or weights. By contrast, the SAQ-global requires patients do this aggregation 
themselves, something that will take place fast, automatically, and with implicit rather 
than conscious consideration of events in a person’s life [23]. Our findings indicate 
that this fast, implicit process can be no worse than that provided by longer 
questionnaires in detecting change. 
Conclusion 
The sensitivity of the ACQ-6, SAQ and SAQ-global to the effect of starting biologic 
treatment is similar. The EQ5D-VAS was less sensitive and the EQ-5D-5L was least 
sensitive to treatment. The comparative sensitivity of PROs varies slightly as a 
function of population and time of assessment, so comparisons with other data sets 
should be treated with caution.  
Our study shows that in clinical practice a rapid increase in quality of life can be 
detected by the SAQ and SAQ-global.  The easy use of the SAQ-global makes it a 
suitable tool if time is limited.  The EQ-5D should not be used in clinical practice to 
evaluate change in quality of life in severe asthma as it is comparatively insensitive 
to change, and the use of this questionnaire in economic decision making may lead 
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